Key facts
- This page summarizes Daniel Lynch's Form 4 filing for SpringWorks Therapeutics, Inc. (SWTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2024, 16:07.
Daniel Lynch - 16 May 2024 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)
- Reporting relationship
- Director
- Issuer ticker
- SWTX
- Reported as of
- 16 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 May 2024, 16:07:14 UTC
- Prior SEC filing
- 15 Jun 2023
- Next SEC filing
- 12 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francis I. Perier, Jr. as Attorney-in Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Lynch filed Form 4 for SpringWorks Therapeutics, Inc. (SWTX) on 17 May 2024.
Change
- Previous filing in this sequence was filed on 15 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SWTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,095
- Change %
- +1.4%
- Price
- $0.000000
- Shares after
- 305,944
- Date
- 16 May 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SWTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,216
- Change %
- Price
- $0.000000
- Shares after
- 12,216
- Date
- 16 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,216
- Exercise price
- $44.77
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 16, 2025 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Footnote F2
This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
Footnote F3
The options shall vest in full on the earlier of (i) May 16, 2025 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.